
Insider Moves: Merus Executive Sells Significant Stock Holdings

I'm PortAI, I can summarize articles.
Merus VP Controller Harry Shuman sold 1,700 shares for $163,370. Merus shareholders approved Genmab's offer to buy all outstanding shares at $97 each, impacting operations and governance. Analysts rate Merus stock as Hold with a $96 target due to weak financials, despite technical momentum. Spark rates MRUS as Neutral, citing declining revenue and losses. Merus's YTD price performance is 127.80%, with a market cap of $7.3B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

